The inflammatory mediator interleukin-1 (IL-1), which is known to be a driver of chronic diseases such as diabetes and hypertension, has recently been identified as a major contributor to ischaemic brain injury. IL-1 is made by the haematopoietic (blood) system and also by cells in the brain. The relative contributions of central versus peripheral sources of IL-1 to brain injury have not been previously investigated. Here, Stuart Allan and colleagues selectively eliminated haematopoietic-derived IL-1 in a chimeric mouse model of ischaemic brain injury. They demonstrate that both sources of IL-1 are important for disease development, but removal of the peripheral source alone is sufficient to improve neurological outcome in the mice. This suggests that therapies that target peripheral IL-1 could be beneficial in brain injury, potentially overriding the need to deliver drugs across the blood-brain barrier. Page 1043
Skip Nav Destination
IN THIS ISSUE| 01 July 2013
Targeting blood-derived IL-1 to treat brain injury
Online Issn: 1754-8411
Print Issn: 1754-8403
Written by editorial staff. © 2013. Published by The Company of Biologists Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Dis Model Mech (2013) 6 (4): 867.
- Views Icon Views
Article Versions Icon
- Version of Record 01 July 2013
- Share Icon Share
- Search Site
Targeting blood-derived IL-1 to treat brain injury. Dis Model Mech 1 July 2013; 6 (4): 867. doi:
Download citation file: